Overview

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Status:
Recruiting

Trial end date:
2027-10-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab